Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Nakanishi, Yutaka ^a   Shiraha, Hidenori ^a   Nishina, Shin ichi ^a   Tanaka, Shigetomi ^a   Matsubara, Minoru ^a   Horiguchi, Shigeru ^a   Iwamuro, Masaya ^a   Takaoka, Nobuyuki ^a   Uemura, Masayuki ^a   Kuwaki, Kenji ^a   Hagihara, Hiroaki ^a   Toshimori, Junichi ^a   Ohnishi, Hideki ^a   Takaki, Akinobu ^a   Nakamura, Shinichiro ^a   Kobayashi, Yoshiyuki ^a   Nouso, Kazuhiro ^a   Yagi, Takahito ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 9; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX3; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; CASPASE; MEMBRANE PROTEIN; ONCOPROTEIN; RUNX3 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; PROTEIN EXPRESSION; CELL GROWTH; CLINICAL ARTICLE; ECTOPIC EXPRESSION; ENZYME ACTIVATION; GROWTH INHIBITION; HEP3B CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; INHIBITION KINETICS; TUMOR ESCAPE; ADOLESCENT; CELL STRAIN HEPG2; CELL SURVIVAL; CULTURE MEDIUM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CULTURE MEDIA, SERUM-FREE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; YOUNG ADULT;

EID: 78650761959     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-30     Document Type: Article

References (45)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
2. Garcia M, Jernal A, Ward EM, M CM, Hao Y, Siegel RI, Thun MJ. Global Cancer Facts & Figures 2007. 2007, Society AC. Atlanta, GA.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94(2):153-156. 10.1002/ijc.1440, 11668491.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340(10):745-750. 10.1056/NEJM199903113401001, 10072408.
5. Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004, 40(5):1047-1052. 10.1002/hep.20460, 15486921.
6. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. The Journal of clinical investigation 2006, 116(6):1582-1595. 10.1172/JCI27236, 1462944, 16710476.
7. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431(7012):1112-1117. 10.1038/nature03043, 15475948.
8. Sicklick JK, Li YX, Melhem A, Schmelzer E, Zdanowicz M, Huang J, Caballero M, Fair JH, Ludlow JW, McClelland RE, et al. Hedgehog signaling maintains resident hepatic progenitors throughout life. American journal of physiology 2006, 290(5):G859-870.
9. Azechi H, Nishida N, Fukuda Y, Nishimura T, Minata M, Katsuma H, Kuno M, Ito T, Komeda T, Kita R, et al. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 2001, 60(4):346-354. 10.1159/000058531, 11408803.
10. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM, Tai MH. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003, 97(8):1929-1940. 10.1002/cncr.11266, 12673720.
11. Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, Hauss J, Wittekind C. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001, 20(48):7104-7109. 10.1038/sj.onc.1204902, 11704835.
12. Yamada T, De Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997, 94(19):10351-10355. 10.1073/pnas.94.19.10351, 23366, 9294214.
13. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 1994, 54(1):281-285.
14. Kawai H, Suda T, Aoyagi Y, Isokawa O, Mita Y, Waguri N, Kuroiwa T, Igarashi M, Tsukada K, Mori S, et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 2000, 31(6):1246-1250. 10.1053/jhep.2000.7298, 10827149.
15. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008, 47(3):908-918. 10.1002/hep.22110, 2865182, 18161048.
16. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003, 163(3):1101-1107. 1868243, 12937151.
17. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000, 10(3):185-200. 10.1006/scbi.2000.0319, 10936068.
18. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 2005, 65(17):7743-7750.
19. Ito Y, Miyazono K. RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 2003, 13(1):43-47. 10.1016/S0959-437X(03)00007-8, 12573434.
20. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem 1999, 274(44):31577-31582. 10.1074/jbc.274.44.31577, 10531362.
21. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 109(1):113-124. 10.1016/S0092-8674(02)00690-6, 11955451.
22. Yamamura Y, Lee WL, Inoue K, Ida H, Ito Y. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 2006, 281(8):5267-5276. 10.1074/jbc.M512151200, 16373335.
23. Araki K, Osaki M, Nagahama Y, Hiramatsu T, Nakamura H, Ohgi S, Ito H. Expression of RUNX3 protein in human lung adenocarcinoma: Implications for tumor progression and prognosis. Cancer Sci 2005, 96(4):227-231. 10.1111/j.1349-7006.2005.00033.x, 15819721.
24. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO, Park JG. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 2004, 23(40):6736-6742. 10.1038/sj.onc.1207731, 15273736.
25. Li J, Kleeff J, Guweidhi A, Esposito I, Berberat PO, Giese T, Buchler MW, Friess H. RUNX3 expression in primary and metastatic pancreatic cancer. J Clin Pathol 2004, 57(3):294-299. 10.1136/jcp.2003.013011, 1770251, 14990603.
26. Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura C, Ito K, Ito Y, et al. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 2004, 23(13):2401-2407. 10.1038/sj.onc.1207395, 14743205.
27. Mori T, Nomoto S, Koshikawa K, Fujii T, Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T, Nakao A. Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int 2005, 25(2):380-388. 10.1111/j.1478-3231.2005.1059.x, 15780064.
28. Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol 2004, 10(3):376-380.
29. Li X, Zhang Y, Qiao T, Wu K, Ding J, Liu J, Fan D. RUNX3 Inhibits Growth of HCC Cells and HCC Xenografts in Mice in Combination With Adriamycin. Cancer Biol Ther 2008, 7(5).
30. Ng IO, Chung LP, Tsang SW, Lam CL, Lai EC, Fan ST, Ng M. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 1994, 9(3):985-990.
31. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K, Ida H, Bouillet P, Strasser A, Bae SC, et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 2006, 26(12):4474-4488. 10.1128/MCB.01926-05, 1489128, 16738314.
32. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, Huang DC. Bim: a novel member of the Bcl-2 family that promotes apoptosis. Embo J 1998, 17(2):384-395. 1170389, 9430630.
33. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Molecular cell 1999, 3(3):287-296. 10.1016/S1097-2765(00)80456-6, 10198631.
34. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96(6):857-868. 10.1016/S0092-8674(00)80595-4, 10102273.
35. Guo C, Ding J, Yao L, Sun L, Lin T, Song Y, Fan D. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer 2005,
36. Osaki M, Moriyama M, Adachi K, Nakada C, Takeda A, Inoue Y, Adachi H, Sato K, Oshimura M, Ito H. Expression of RUNX3 protein in human gastric mucosa, intestinal metaplasia and carcinoma. Eur J Clin Invest 2004, 34(9):605-612. 10.1111/j.1365-2362.2004.01401.x, 15379759.
37. Torquati A, O'Rear L, Longobardi L, Spagnoli A, Richards WO, Daniel Beauchamp R. RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery 2004, 136(2):310-316. 10.1016/j.surg.2004.05.005, 15300196.
38. Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, Kim WJ, Lee KY, Bae SC. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 2004, 279(28):29409-29417. 10.1074/jbc.M313120200, 15138260.
39. Li G, Wang S, Gelehrter TD. Identification of glucocorticoid receptor domains involved in transrepression of transforming growth factor-beta action. J Biol Chem 2003, 278(43):41779-41788. 10.1074/jbc.M305350200, 12902338.
40. Mouri H, Sakaguchi K, Sawayama T, Senoh T, Ohta T, Nishimura M, Fujiwara A, Terao M, Shiratori Y, Tsuji T. Suppressive effects of transforming growth factor-beta1 produced by hepatocellular carcinoma cell lines on interferon-gamma production by peripheral blood mononuclear cells. Acta Med Okayama 2002, 56(6):309-315.
41. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350(6317):429-431. 10.1038/350429a0, 1672732.
42. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999, 19(3):235-242. 10.1055/s-2007-1007113, 10518303.
43. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, Mayer RJ, Arii S, Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nature medicine 2000, 6(1):96-99. 10.1038/71600, 10613832.
44. Hsia CC, Di Bisceglie AM, Kleiner DE, Farshid M, Tabor E. RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. Journal of medical virology 1994, 44(1):67-73. 10.1002/jmv.1890440113, 7798888.
45. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 1998, 95(26):15406-15411. 10.1073/pnas.95.26.15406, 28055, 9860981.